Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa

References

• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1–266
   PubMed Web of Science ®Google Scholar
• Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Inter Med J 2004;34:50–7
   Google Scholar
• Klang B, Bjorvell H, Clyne N. Quality of life in predialytic uremic patients. Qual Life Res 1996;5:109–16
   PubMed Web of Science ®Google Scholar
• Evans RW, Rader B, Manninen DL. Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990;263:825–30
   Google Scholar
• Lowrie EG, Ling J, Lew NL, et al. The relative contribution of measured variables to death risk among hemodialysis patients, In: Friedman EA, editor. Death on hemodialysis: preventable or inevitable? Boston, MA: Kluwer Academic Publishers, 1994, pp.121–41
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia of chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3): S1–146
   Google Scholar
• Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004;60:392–405
   Google Scholar
• Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is selected hemodialysis patients. J Am Soc Nephrol 2000;11: 335–42
   PubMed Web of Science ®Google Scholar
• Furuland H, Linde T, Ahlmén J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353–61
   Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Eng J Med 1998;339:584–90
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Pickett JL, Theberge DC, et al. Brain function is better in hemodialysis patients when hematocrit is normalized with erythropoietin. J Am Soc Nephrol 1996;7:1459 [abstract]
   Google Scholar
• Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548–54
   PubMed Web of Science ®Google Scholar
• Grimm G, Stockenhuber F, Schneeweiss B, et al. Improvement of brain function in haemodialysis patients treated with erythropoietin. Kidney Int 1990;38:1–7
   Google Scholar
• Lundin AP, Akerman MJH, Chesler RM, et al. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron 1991;58:315–9
   PubMed Web of Science ®Google Scholar
• Auer J, Oliver DO, Winearls CG. The quality of life of dialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol Suppl 1990;131:61–5
   Google Scholar
• Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996;7:763–73
   PubMed Web of Science ®Google Scholar
• Churchill DN, Muirhead N, Goldstein M, et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995;43:184–8
   PubMed Web of Science ®Google Scholar
• Harris DCH, Chapman JR, Stewart JH. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 1991;21:693–700
   Google Scholar
• Iseki K, Nishime K, Uehara H, et al. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1996;72:30–6
   PubMedGoogle Scholar
• Mayer G, Thum J, Cada EM, et al. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988;34:525–8
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemo-therapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888–95
   PubMed Web of Science ®Google Scholar
• Shasha D, Cremieux P, Harrison L. Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa. J Natl Compr Canc Netw 2004;2:509–17
   Google Scholar
• Nortier JWR, Zagari M, Chen Y. Marginal analysis to identify optimal hemoglobin levels to maximize quality of life improvement in anemic cancer patients receiving epoetin alfa. 25th Congress of the European Society for Medical Oncology, Hamburg, Germany, 13–17 October 2000 [abstract 6660].
   Google Scholar
• Gough IR, Furnival CM, Schilder L, et al. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983;19:1161–5
   PubMedGoogle Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412–25
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–82
   PubMed Web of Science ®Google Scholar
• Laupacis A, Muirhead N, Keown, et al. A disease-specific questionnaire for assessing quality of life in patients on hemo-dialysis. Nephron 1992;60:302–6
   PubMedGoogle Scholar
• Valderrábano F, Jofre R, López-Gómez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis 2001;38: 443–64
   PubMed Web of Science ®Google Scholar
• Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Contr Clin Trials 1991;12:168S–79
   Google Scholar
• McGuigan JR, Moyer C, Harris FH. Managerial economics. 7th edn. St Paul: West Publishing Company, 1996
   Google Scholar
• Heckman JJ. Sample selection bias as a specification error. Econometrica 1979;47:153–61
   Web of Science ®Google Scholar
• Spilker B. Quality of life and pharmacoeconomics in clinical trials. 2nd edn. Philadelphia: Lippincott Williams and Wilkins, 1996
   Google Scholar
• Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335–45
   PubMed Web of Science ®Google Scholar
• Irvine D, Vincent L, Graydon JE, et al. The prevalence and correlates of fatigue in patients receiving treatment with chemo-therapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs 1994;17: 367–78
   Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74
   PubMed Web of Science ®Google Scholar
• Barnett A, Crémieux PY, Fendrick MA, et al. Anemia related costs for cancer patients. J M C Med 2002;6:20–8
   Google Scholar
• Cella D, Dobrez D, Glaspy JA. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511–9
   Google Scholar
• Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353–60
   PubMedGoogle Scholar
• Cella D, Peterman A, Passik S, et al. Progress toward guidelines for the management of fatigue. Oncology 1998;12:369–77
   PubMed Web of Science ®Google Scholar
• Hillman RS, Finch CA. Erythropoietin regulation of erythropoiesis. In: Red Cell Manual. 7th edn. Philadelphia, Pa: FA Davis Company, 1996, p.25
   Google Scholar